Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian CancerBusiness Wire • 10/31/24
Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual MeetingBusiness Wire • 10/17/24
Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual MeetingBusiness Wire • 10/09/24
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire • 10/07/24
Verastem Oncology to Present Mature RAMP 201 Data in Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society 2024 Annual MeetingBusiness Wire • 09/10/24
Verastem Oncology and STAAR Ovarian Cancer Foundation Establish the Inaugural Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day on September 9, 2024Business Wire • 09/03/24
Verastem Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business UpdatesBusiness Wire • 08/08/24
Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic CancerBusiness Wire • 07/29/24
Verastem Oncology Announces Pricing of $55.0 Million Public Offering of Common Stock, Warrants and Pre-Funded WarrantsBusiness Wire • 07/24/24
Verastem Oncology Announces Proposed Public Offering of Common Stock, Warrants and Pre-Funded WarrantsBusiness Wire • 07/23/24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verastem, Inc. - VSTMAccesswire • 07/14/24
Verastem Oncology Announces First Patient Dosed with GFH375/VS-7375, a KRAS G12D (ON/OFF) Inhibitor, in a Phase 1/2 Trial in China as Part of Collaboration with GenFleet TherapeuticsBusiness Wire • 07/12/24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verastem, Inc. - VSTMGlobeNewsWire • 07/07/24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Verastem, Inc. - VSTMAccesswire • 07/05/24
Verastem Oncology Announces Addition to Russell 3000® and Russell Microcap® IndexesBusiness Wire • 07/01/24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Verastem, Inc. – VSTMGlobeNewsWire • 06/30/24
VERASTEM ALERT: Bragar Eagel & Squire, P.C. is Investigating Verastem, Inc. on Behalf of Verastem Stockholders and Encourages Investors to Contact the FirmGlobeNewsWire • 06/10/24
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Verastem, Inc. (VSTM)Business Wire • 06/07/24